Outcomes in Patients Undergoing Cardiac Surgery Who Decline Transfusion and Received Erythropoietin Compared to Patients Who Did Not: A Matched Cohort Study.

Thumbnail Image



Journal Title

Journal ISSN

Volume Title

Repository Usage Stats


Citation Stats


BACKGROUND: Erythropoiesis-stimulating agents, such as erythropoietin (EPO), can be used to treat preoperative anemia. Some studies suggest an increased risk of mortality and thrombotic events, and use in cardiovascular surgery remains off-label. This study compares outcomes in cardiac surgery patients declining blood transfusion who received EPO with a matched cohort who did not. METHODS: After institutional review board approval, we conducted a retrospective review of all patients who decline blood transfusion who underwent cardiac surgery and received EPO between January 1, 2004, and June 15, 2015, at a single institution. Control patients who did not receive EPO and were not transfused allogeneic red blood cells perioperatively were identified during the same period. Two controls were matched to each EPO patient using an optimal matching algorithm based on age, date of surgery, gender, operative procedure, and surgeon. The European System for Cardiac Operative Risk Evaluation (EuroSCORE) and baseline characteristics remaining unbalanced in the matched cohorts were controlled for in assessing patient outcomes. The primary outcome was a composite of mortality and thrombotic events, and secondary outcomes included change in hemoglobin (Hb) from baseline to discharge, acute kidney injury (AKI), sternal wound infection, atrial fibrillation, time to extubation, intensive care unit, and hospital length of stay (LOS). RESULTS: Fifty-three patients who decline transfusion and received EPO were compared to 106 optimally matched control patients who did not receive EPO or red blood cell transfusion in the perioperative period. The median additive EuroSCORE was similar between the EPO and control group [6 (4, 9) vs 5 (3, 7), respectively; P = .39]. There was no difference in the primary outcome (P = .12) and mortality was zero in both groups. The EPO group had a higher mean preoperative Hb (13.91 g/dL vs 13.31; P = .02) and a smaller change in Hb from baseline (-2.65 vs -3.60; P = .001). The incidence of AKI (47.17% vs 41.51%; P = .49) was similar and there was no significant difference in all other outcomes, including time to extubation, hospital LOS, or intensive care unit LOS. CONCLUSIONS: In this retrospective matched cohort study of patients declining transfusion and receiving EPO matched to control patients, there were no clinically meaningful differences in the outcomes.






Published Version (Please cite this version)


Publication Info

Duce, Lorent, Mary L Cooter, Sharon L McCartney, Frederick W Lombard and Nicole R Guinn (2017). Outcomes in Patients Undergoing Cardiac Surgery Who Decline Transfusion and Received Erythropoietin Compared to Patients Who Did Not: A Matched Cohort Study. Anesth Analg. 10.1213/ANE.0000000000002418 Retrieved from https://hdl.handle.net/10161/15972.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.




Sharon Lorraine McCartney

Associate Professor of Anesthesiology

Nicole Renee Guinn

Professor of Anesthesiology

Originally from Anchorage, Alaska, Dr. Guinn attended Mount Sinai School of Medicine in New York, NY, where she graduated with AOA honors.  She then completed her anesthesiology residency and fellowship in cardiothoracic anesthesia at Duke University Medical Center, staying on as faculty after completing her training. Dr. Guinn served as the Medical Director of the Center for Blood Conservation at Duke University Medical Center from 2013-2022, working with patients who decline transfusion to receive safe care and improved outcomes, and developing an institutional Preoperative Anemia Clinic to diagnose and treat anemia in operative patients at risk for transfusion. She is known nationally for her expertise in management of patients “When Blood is Not an Option” and for preoperative optimization of anemia in surgical patients and is the current Chair for the ASA Committee on Patient Blood Management.  Dr. Guinn is also involved with the American Board of Anesthesiology, serving as an OSCE Committee member and APPLIED examiner for board certification in the anesthesiology. She is the current Interim Division Chief of neuro-anesthesiology, otolaryngology and offsite anesthesia at Duke University.